How to explore and definition of a more standardized and comprehensive approach for the detection of PD-L1 on both tumor cells and immune cells, how to screen patients who may benefit greatly but have less immune-related adverse reactions, how to individualize and optimize treatment, etc. These are all problems that need to be solved in the future. This evidence concerns the gene CD274 and neoplasm.